[1] |
高亚,魏巍,罗鑫悦,等.单个病例数据Meta分析引用情况研究[J]. 中国药物评价,2019,36(5):330-335.
|
[2] |
田金徽,夏淼,杨克虎,等.单个病例数据Meta分析合作能力研究[J]. 中国药物评价,2019,36(5):321-325.
|
[3] |
魏巍,夏淼,高亚,杨克虎,等.单个病例数据Meta分析的研究主题分析[J]. 中国药物评价,2019,36(5):326-329.
|
[4] |
田金徽,Fujian Song,杨克虎,等.单个病例数据Meta分析的起源与发展[J]. 中国药物评价,2019,36(4):241-244,263.
|
[5] |
田金徽,杨克虎,Fujian Song,等.单个病例数据Meta分析研究现状[J]. 中国药物评价,2019,36(4):245-251.
|
[6] |
田金徽,李伦主编.网状meta分析方法与实践[M]. 北京:中国医药科技出版社,2017.
|
[7] |
Signorovitch JE, Sikirica V, Erder MH, et al.Matching-adjusted indirect comparisons: a new tool for timely comparative effectiveness research[J]. Value Health, 2012, 15(6):940-947.
|
[8] |
Veroniki AA, Straus SE, Soobiah C, et al.A scoping review of indirect comparison methods and applications using individual patient data[J]. BMC Med Res Methodol, 2016, 27;16:47.
|
[9] |
Ishak KJ, Proskorovsky I, Benedict A. Simulation and matching-based approaches for indirect comparison of treatments[J]. Pharmacoeconomics, 2015, 3(6):537-549.
|
[10] |
Jansen JP. Network meta-analysis of individual and aggregate level data[J]. Res Synth Methods, 2012, 3(2):14.
|
[11] |
Donegan S, Williamson P, D′Alessandro U, et al. Assessing the consistency assumption by exploring treatment by covariate interactions in mixed treatment comparison meta-analysis: Individual patient-level covariates versus aggregate trial-level covariates[J]. Stat Med, 2012, 31(29):3840-3857.
|
[12] |
Higgins J, Whitehead A, Turner RM, et al. Meta-analysis of continuous outcome data from individual patients[J]. Stat Med, 2001, 20:2219-2241.
|
[13] |
Berlin JA, Santanna J, Schmid CH, et al. Individual patient- versus group-level data meta-regressions for the investigation of treatment effect modifiers: ecological bias rears its ugly head[J]. Stat Med, 2002, 21(3):371-387.
|
[14] |
Cooper H, Patall EA. The relative benefits of meta-analysis conducted with individual participant data versus aggregated data[J]. Psychol Methods, 2009, 14(2):165-176.
|
[15] |
Saramago P, Sutton AJ, Cooper NJ, et al. Mixed treatment comparisons using aggregate and individual participant level data[J]. Stat Med, 2012, 31(28):3516-3536.
|
[16] |
Freeman SC, Fisher D, Tierney JF, et al. A framework for identifying treatment-covariate interactions in individual participant data network meta-analysis[J]. Res Synth Methods, 2018, 9(3):393-407.
|
[17] |
Saramago P, Woods B, Weatherly H, et al. Methods for network meta-analysis of continuous outcomes using individual patient data: a case study in acupuncture for chronic pain[J]. BMC Med Res Methodol, 2016, 16(1):131.
|
[18] |
Malangone E, Casciano R, Sherman S, et al. A novel approach to matching adjusted indirect comparison analysis using common sas 9.2 procedures[J]. Value in Health, 2010, 13:17.
|
[19] |
Signorovitch JE, Sikirica V, Erder MH, et al. Matching-adjusted indirect comparisons: a new tool for timely comparative effectiveness research[J]. Value in Health, 2012, 15(6):940-947.
|
[20] |
Signorovitch J, Ayyagari R, Cheng D, et al. Matching-adjusted indirect comparisons: A simulation study of statistical performance[J]. Value in Health, 2013, 16:3.
|
[21] |
Shafrin J, Sikirica V, Shrestha A, et al. Methodological assessment of matching-adjusted indirect comparisons: Case study application to attention deficit/hyperactivity disorder (ADHD)[J]. Value in Health, 2013, 17:7.
|
[22] |
Alsop JC, Regnier SA, Wright JJ. A novel ITC approach: Matching patient-level data to study-level summary means and variances[J]. Value in Health, 2015, 18:7.
|
[23] |
Belger M, Brnabic A, Kadziola Z, et al. Alternative weighting approaches for matching adjusted indirect comparisons (MAIC)[J]. Value in Health, 2015, 18:3.
|
[24] |
Thom H, Jugl SM, Nikoglou E, et al. Matching-adjusted indirect comparisons to assess comparative effectiveness: A systematic review of application in scientific literature and health technology appraisals[J]. Value in Health, 2017, 20:5.
|
[25] |
Phillippo DM, Ades AE, Dias S, et al.Methods for Population-Adjusted Indirect Comparisons in Health Technology Appraisal[J]. Medical decision making, 2018, 38:2
|
[26] |
Alsop J, Pont L, Scott M, et al.Which matching adjusted indirect comparison method is best[J]. Int J Technol Assess, 2019, 35, (Sup 1):94-95.
|
[27] |
Caro JJ, Ishak KJ. No head-to-head trial? Simulate the missing arms[J]. Pharmacoeconomics, 2010, 28(10):957-967.
|
[28] |
Proskorovsky I, Benedict A, Larkin JMG, et al. Axitinib (AXI) and best supportive care (BSC) in the treatment of sunitinib-refractory patients with metastatic renal cell carcinoma (MRCC): Results of a simulated treatment comparison (STC) analyses[J]. Value in Health, 2012, 15:7.
|
[29] |
Batson S, Mitchell SA, King D. The use and acceptance of novel statistical analyses to support technology submissions to HTA authorities[J]. Value in Health, 2014, 17:7.
|
[30] |
Ishak KJ, Rael M, Phatak H, et al. Simulated treatment comparison of time-to-event (and ot her non-linear) outcomes[J]. Value in Health, 2015, 18:7.
|
[31] |
Shukla P, Sharma A, Siddiqui MK. A comparison of patient level data (IPD) regression techniques in adjusting for cross trial differences in an indirect treatment comparison (ITC): A worked example of simulated treatment comparison (STC) vs bayesian IPD regression[J]. Value in Health, 2018, 21:S228.
|
[32] |
Donegan S, Williamson P, D′Alessandro U, et al. Assessing the consistency assumption by exploring treatment by covariate interactions in mixed treatment comparison meta-analysis: individual patient-level covariates versus aggregate trial-level covariates[J]. Stat Med, 2012, 31(29):3840-3857.
|
[33] |
Saramago P, Sutton AJ, Cooper NJ, et al. Mixed treatment comparisons using aggregate and individual participant level data[J]. Stat Med, 2012, 31(28):3516-3536.
|
[34] |
Donegan S, Williamson P, D′Alessandro U, et al. Combining individual patient data and aggregate data in mixed treatment comparison meta-analysis: Individual patient data may be beneficial if only for a subset of trials[J]. Stat Med, 2013, 32(6):914-930.
|
[35] |
Saramago P, Chuang LH, Soares MO. Network meta-analysis of (individual patient) time to event data alongside (aggregate) count data[J]. BMC Med Res Methodol, 2014, 14:105.
|
[36] |
Freeman S, Carpenter J, Tierney J. One-step individual patient data (IPD) network meta-analysis of survival data using royston-parmar models[J]. Trials, 2015, 16(Sup2):161.
|
[37] |
Thom HH, Capkun G, Cerulli A, et al. Network meta-analysis combining individual patient and aggregate data from a mixture of study designs with an application to pulmonary arterial hypertension[J]. BMC Med Res Methodol, 2015, 15:34.
|
[38] |
Dagne GA, Brown CH, Howe G, et al.Testing moderation in network meta-analysis with individual participant data[J]. Stat Med, 2016, 35(15):2485-2502.
|
[39] |
Normand SL, Spertus J, Horvitz-Lennon M. Network meta-analysis of causal dose-response relationships using individual participant trial data[J]. Biological Psychiatry, 2017, 81(Sup10):S34-S35.
|
[40] |
Freeman SC, Fisher D, Tierney JF, et al. A framework for identifying treatment-covariate interactions in individual participant data network meta-analysis[J]. Res Synth Methods, 2018, 9(3):393-407.
|
[41] |
Debray TPA, Schuit E, Efthimiou O, Reitsma JB, et al. An overview of methods for network meta-analysis using individual participant data: when do benefits arise[J]. Stat Methods Med Res, 2018, 27(5):1351-1364.
|